How MammaPrint Is Reshaping Treatment Decisions in HR+/HER2– Breast Cancer

In this interview with Pharmacy Times, Lee Schwartzberg, MD, FACP, discusses how genomic profiling with MammaPrint and BluePrint helps identify patients with HR-positive, HER2-negative breast cancer who can safely avoid anthracycline-based chemotherapy without compromising outcomes. He explains how low- and ultra-low–risk patients derive sufficient benefit from endocrine therapy alone, while high-risk patients benefit from more aggressive regimens, including anthracyclines. Schwartzberg highlights the importance of integrating genomic data with clinical and patient-specific factors to support personalized treatment decisions. He also emphasizes the critical role of pharmacists in multidisciplinary care teams, particularly in guiding testing decisions, educating patients, and managing chemotherapy-related toxicities.